Did Timothy Leary have it right? There is more interest these days in research into the use of psychedelic drugs as a therapy for many conditions and the FDA is getting on board by publishing a guidance document entitled Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry (here). The guidance notes that the “U.S. […]
In a complete supply chain, one site’s lag measure is another site’s lead measure. As important as data integrity is to product quality decisions at the site, data risks in the supply chain can affect availability of product to patients. As mentioned in a previous Lachman blog (here), drug shortages are the preeminent risk for […]
Many of our clients and readers have NDAs, ANDAs, and supplements that are still pending approval due to a “complex regulatory issue” where the FDA has missed its goal date; in some cases, this missed date was many months ago. There can be several reasons for this type of delay but, as we have blogged […]
Prescription Medication Information (PMI) will, if FDA has its way, replacing medication guides and other information provided to patients. The goal of the new PMI is to “highlight essential information that the patient needs to know about the prescription drug product and basic directions on how to use the product. The pre-publication of the proposed […]
We are pleased to announce that Lachman Consultants (Ireland) will participate in this year’s MedTech Forum as a Gold sponsor. Held from May 30 – June 1, 2023, in Dublin, Ireland, the three-day event is the largest health and medical technology industry conference in Europe. The Lachman Consultants team will be represented by: Frances Zipp, […]
The Food and Drug Law Institute (FDLI) recently held its 2023 Annual Conference on May 17-18 in Washington, D.C. where professionals from the food, drug, medical device, biologics, and tobacco industries gathered to hear important updates and panel discussions from a distinguished group of industry and FDA speakers. The Conference commenced with keynote addresses by […]
One of the breakout sessions offered at the recent FDLI conference was titled, Updates on Patent and Exclusivity Issues for Drugs, Orphan Drugs and Biologics. The panel for this session included representatives from FDA, industry, and attorneys that specialize in this practice area. While the session covered both patent and exclusivity issues, I will be […]
Hundreds of FDA staff, industry professionals, lawyers, and others gathered in Washington, D.C. on May 17th and 18th to participate in the 2023 Food and Drug Law Institute (FDLI) Annual Conference. The agenda covered a broad range of current regulatory and legal issues facing the food, drug, medical device, biologics, and tobacco industries. Lachman Consultant Services […]
In the prepublication of the Federal Register (here) which will publish on May 15, 2023, the FDA announced that Makena (Hydroxyprogesterone Caproate injection) will be removed from the Orange Book (OB) along with eight (8) generic applications that referenced Makena as the RLD in its application. Makena was originally approved in 2011 under the accelerate […]
Based on the longstanding knowledge that diethylene glycol (DEG) and ethylene glycol (EG) are dangerous at levels that may exceed USP‑NF limits and because of the recent misadventures and deaths resulting from these incidents, the FDA has revised a 2007 guidance to provide further recommendations regarding the identification and quantification of these contaminants in drug […]
